Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium

Gastroenterology(2021)10.1053/j.gastro.2021.07.033Source: DataRank Database

Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium is a research paper published in Gastroenterology (2021). On theSindex it has a DataRank of 0. It has been cited 150 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access150 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 11.35)OA: greenTopics (112)Linked Datasets (10)DataCite Reuse (10)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Catherine Frenette ORCID,Parissa Tabrizian ORCID,Maarouf Hoteit ORCID,Jennifer Guy ORCID,Neehar D. Parikh ORCID

Live enrichment

PubMed:34331914 PMC:PMC8545832 OpenAlex:https://openalex.org/W3184850586

National Institutes of Health

Grant: P30 DK026743

NCI NIH HHS

Grant: K08 CA222676

National Institutes of Health

Grant: 5P30DK026743-27

UCSF Liver Core Center

Genentech

Liver Center, University of California, San Francisco

Bayer Fund

Eli Lilly and Company

Eisai

Exelixis

National Institute of Diabetes and Digestive and Kidney Diseases

FWCI

11.35

Citation Percentile

1.0%

Influential Citations

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8545832

GREENhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545832

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8545832

publisherhttps://api.elsevier.com/content/article/PII:S0016508521032844?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0016508521032844?httpAccept=text/plain

Fields of Study

Hepatocellular Carcinoma Treatment and PrognosisOrgan Transplantation Techniques and OutcomesCholangiocarcinoma and Gallbladder Cancer StudiesMedicine0302 clinical medicine03 medical and health sciencesAgedCarcinoma, HepatocellularChemoembolization, TherapeuticDisease ProgressionFeasibility StudiesFemaleHumansLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPatient DropoutsProspective StudiesRadiopharmaceuticalsRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeTumor BurdenUnited StatesWaiting Lists

MeSH Terms

AgedFeasibility StudiesFemaleCarcinoma, HepatocellularHumansLiver NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPatient DropoutsProspective StudiesRisk FactorsTime FactorsUnited StatesWaiting ListsLiver TransplantationChemoembolization, TherapeuticTreatment OutcomeDisease ProgressionRisk AssessmentRadiopharmaceuticalsTumor Burden

Keywords

Hepatocellular carcinomaLiver transplantationMedicineReduction (mathematics)Milan criteriaTransplantationInternal medicineMulticenter studyOncologyRandomized controlled trialMathematicsTumor RecurrenceΑ-fetoprotein (Afp)Local Regional Therapy (Lrt)Waiting List DropoutMaleTime FactorsClinical sciencesLocal Regional TherapyRisk FactorsProspective StudiesCancerLiver DiseaseLiver NeoplasmsMiddle AgedTumor BurdenTreatment OutcomeLocalDisease ProgressionChemoembolizationFemaleTherapeuticα-FetoproteinLiver CancerCarcinoma, HepatocellularPatient DropoutsWaiting ListsRisk AssessmentPaediatrics and Reproductive MedicineRare DiseasesClinical Research617Humansalpha-FetoproteinChemoembolization, TherapeuticAgedNeoplasm StagingBiomedical and Clinical SciencesGastroenterology & HepatologyCarcinomaNeurosciencesHepatocellularOrgan TransplantationUnited StatesNutrition and dieteticsNeoplasm RecurrenceFeasibility StudiesNeoplasm Recurrence, LocalRadiopharmaceuticalsDigestive Diseases

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 4 of Predicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features

10.6084/m9.figshare.24130166.v1figshare

Additional file 4 of Predicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features

10.6084/m9.figshare.24130166figshare

Additional file 5 of Predicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features

10.6084/m9.figshare.24130169.v1figshare

Additional file 5 of Predicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features

10.6084/m9.figshare.24130169figshare

Additional file 2 of Predicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features

10.6084/m9.figshare.24130160figshare

Additional file 3 of Predicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features

10.6084/m9.figshare.24130163.v1figshare

Additional file 1 of Predicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features

10.6084/m9.figshare.24130157figshare

Additional file 3 of Predicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features

10.6084/m9.figshare.24130163figshare

Additional file 2 of Predicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features

10.6084/m9.figshare.24130160.v1figshare

Additional file 1 of Predicting the outcomes of hepatocellular carcinoma downstaging with the use of clinical and radiomics features

10.6084/m9.figshare.24130157.v1figshare